Combination therapy in pulmonary arterial hypertension: do we have the right strategy?

Abstract

The management of pulmonary hypertension has already incorporated the use of multiple therapies into routine practice. Available therapies act principally through vasodilatation of the pulmonary arterial circulation through well-delineated mechanisms, although right ventricular function determines function and prognosis. Therefore, the goal of these therapies is effectively to preserve right ventricular function through reducing right ventricular afterload. The clinical trial experience of combination therapy is limited and the optimal combinations and administration strategies have yet to be clarified.

Keywords::

• combination therapy
• de novo therapy
• goal-oriented approach
• pulmonary hypertension

Financial & competing interests disclosure

Luke Howard has received honoraria from Actelion, GlaxoSmithKline, Pfizer, Bayer and Novartis. He is in receipt of research grants from Pfizer and Bayer. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.